Masonic Cancer Center

A comprehensive cancer center designated by the National Cancer Institute

Masonic Cancer Center Update Newsletter

What You See Is What You Get Element

  Masonic Cancer CC Update Banner

Update is available on the web at

Update is an official newsletter of the Masonic Cancer Center for faculty, members, staff, colleagues, and friends.All submissions for the next issue must be sent to, by noon on Friday for publication the following Monday.

Want to stay updated between Updates?

Follow us on Twitter and Facebook!

February 8, 2016

Tuesday Seminar

Tuesday, February 9, 2016, 1-125 CCRB (simulcast in 450 MCRB, Hormel Institute room 155, and Duluth room 112-SMed)
William Elmquist, PharmD, Ph.D., Professor, Department of Pharmaceutics, Director, Brain Barriers Research Center, University of Minnesota, Research member, Tumor Microenvironment Program

Host: Jim McCarthy, Ph.D.

A peek at the next seminar:
Tuesday, February 16, 2016, 1-125 CCRB (simulcast in 450 MCRB, Hormel Institute room 155, and Duluth room 112-SMed)
DICER1 syndrome tumors: Clinical genetics and tumor pathogenesis
D. Ashley Hill, M.D., Chief, Division of Pathology, Children's Research Institute, Children's National Health System

Kris Ann Schultz, M.D., Hematology-Oncology, Pediatric Physician, Children's Hospitals and Clinics of Minnesota

Host: David Largaespada, Ph.D.

View the calendar for a complete schedule.

In This Issue


Program Meetings

Translational Working Group Meetings

Professional Education


Funding Announcements and Opportunities

Employment Opportunities


Members in the news

  • DeAnn Lazovich, Ph.D., M.P.H., Screening, Prevention, Etiology and Cancer Survivorship program, was quoted in stories about her research showing indoor tanning can heighten melanoma risk sixfold. See Huffington PostRegal Tribune,Lighthouse News Daily, ReutersLatinos HealthLive Mint.
  • Ghautam Jha, M.D., is featured in a story of the Big Ten Cancer Research Consoritium’s website about a poster presentation at the 2016 Genitourinay Cancers Symposium in San Francisco, where he and other colleagues presented data on the Phase 1B portion of a clinical trial establishing the maximum tolerated dose of pembrolizumab and bevacizumab in combination for subjects with metastatic clear cell renal carcinoma after failure of at least one systemic therapy for metastatic disease.  The trial is now a Phase 2 ongoing trial. 
  • Louise Mansky, Ph.D., Genetic Mechanisms of Cancer Program is quoted in reports on his research identifying how drug target blocks HIV’s ability to spread.  Eureka Alert, Health Talk, Infection Control Today.

Members receive grants

  • David Largaespada, Ph.D., Genetic Mechanisms of Cancer Program, has received a $1.8 million grant from Children's Tumor Foundation, for his project, "An innovative NF1 drug discovery pipeline for preclinical development of novel drugs quickly, safely, and effectively".

    The University of Minnesota has assembled a team including basic biologists, animal modelers, imaging specialists, clinical experts, pharmacologists, and industry partners to establish a drug discovery pipeline in an effort to move drugs rapidly through preclinical assessment and into clinical trials for people suffering from complications of NF1. The team is led by Dr. Largaespada. The research team plans to test thousands of new compounds initially in the lab for potential efficacy and specificity against human cells that have the NF1 mutation. Compounds that show promise will then be tested in mice and then into a large animal model of NF1, the final stages of preclinical testing before trials can be done in humans. The research team is partnering with Recombinetics, a biotechnology company based in St. Paul, Minnesota, to develop a pig model which will be used to test promising drugs identified by the researchers.
  • Bruce Blazar, M.D., Transplant Biology and Therapy Program, Brian Fife, Ph.D., Immunology Program, and John Wagner, M.D., Transplant Biology and Therapy Program, were among nine principal investigators receiving grants for Regenerative Medicine Minnesota, a joint venture between the University of Minnesota and Mayo Clinic funded by the Minnesota Legislature.  Blazar's grant will fund a study to improve the in vivo efficacy and safety of blood-forming cells, derived from induced pluripotent stem cells, to treat patients with a wide range of diseases. Fife's grant will fund a study to identify and target malfunctioning T cells that cause Type 1 diabetes. Wagner's grant will fund a clinical trial that demonstrates the ability of StemRegenin1based, blood-forming cells to reduce neutropenia. Read more.

Members in the journals
The laboratory of Greg Metzger, Ph.D., Tumor Microvenvironment Program, has recently published three papers:

  • Erturk MA, Tian J, Van de Moortele PF, Adriany G, Metzger GJ. Development and evaluation of a multichannel endorectal RF coil for prostate MRI at 7T in combination with an external surface array. J Magn Reson Imaging 2015 [Epub ahead of print].
  • Metzger GJ, Kalavagunta C, Spilseth B, Bolan PJ, Li X, Hutter D, Nam JW, Johnson AD, Henriksen JC, Moench L, Konety B, Warlick CA, Schmechel SC, Koopmeiners JS. Detection of Prostate Cancer: Quantitative Multiparametric MR Imaging Models Developed Using Registered Correlative Histopathology. Radiology 2016 [Epub ahead of print].
  • Kobayashi N, Goerke U, Wang L, Ellermann J, Metzger GJ, Garwood M. Gradient-Modulated PETRA MRI. Tomography 2015;1:85-90.

Members speak at conferences
Anindya Bagchi, Ph.D., Genetic Mechanisms of Cancer Program, has been selected to give an oral presentation on his research, “Insights into the oncogenic basis of long-con-coding RNA PVT1 in human cancer,” at the American Association for Cancer Research annual meeting in New Orleans, April 16-20, 2016.

State Cancer Plan Update – The Minnesota Cancer Alliance requests your participation in a brief survey
The Minnesota Cancer Alliance is in the process of updating Cancer Plan Minnesota 2011-2016.  Between now and the end of February 2016, the Alliance is collecting public comments about how Minnesota can improve in the areas of cancer prevention, detection, treatment and survivorship, each with a focus on health equity.  By clicking on the link below, you can offer your ideas via three open-ended questions about what is working well and what could work better to reduce the cancer burden in Minnesota.  Please participate!

Back to top

Program Meetings

BMT Program Meeting
Monday, February 8, 2016, 1:15-2:15 p.m., 450 MCRB
Tandem Practice Presentations:
Improved graft-versus-host disease-free, relapse-free survival (GRFS) associated with bone marrow as the stem cell source
Rohtesh Mehta, M.D., M.P.H., M.S.

Parental Perspectives: Long-term functioning of patients with Hurler Syndrome and adrenoleukodystrophy following HSCT
Rachel Phelan, M.D.

Back to top

Translational Working Group Meetings

Prostate Cancer Translational Working Group
February 9, 2016, 8-9 a.m., B-564 Mayo
Thomas Griffith, Ph.D., Associate Professor, Department of Urology, will present his pilot project final report.

Brain Tumor Translational Working Group
February 11, 2016: 9 a.m., 3-150 CCRB
Using targeted nucleases for neuro-oncology research: New genes and new methods
David Largaespada, Ph.D. and Alex Larsson

Cutaneous Oncology Translational Working Group
February 11, 2016, 11:30 a.m.-12:30 p.m.,  8-225 PWB
Update on TWG pilot: quality of life and sun protection behaviors in melanoma survivors versus controls presented by DeAnn Lazovich, Ph.D.,  and Rachel Isaksson Vogel, Ph.D.

Back to top

Professional Education

February 9, 2016: Tobacco Research Studies Meeting
2 p.m., room 105, 717 Delaware St. SE
Building tobacco research capacity in India: A critical resource for cancer prevention and
tobacco control efforts
Irina Stepanov, Ph.D., Assistant Professor, Division of Environmental Health Sciences
School of Public Health, University of Minnesota

Samir Khariwala, M.D., Associate Professor, Department of Otolaryngology, Head and Neck Surgery, University of Minnesota
We will discuss progress and challenges of our work on setting up a clinical site and analytical
laboratory in Mumbai. Currently, this resource is being used to investigate the relationship between tobacco carcinogen exposure and risk of oral cancer in India. Future biomarker‐based research opportunities utilizing this resource will also be discussed.

February 10, 2016: Cancer Biology Research Club
12-1 p.m., 2-115 CCRB
Investigating PR/PELP1 cross-talk in breast cancer
Katherine Leehy, Ph.D., Cancer Biology Training Grant postdoctoral fellow, Lange lab

February 15, 2016: Chemical Biology Colloquium
12:15 p.m., room 105, 717 Delaware St. SE
PROTACS: Induced protein degradation as a therapeutic strategy
Craig Crews, Lewis B. Cullman Professor, Department Molecular, Cellular, and Developmental Biology, Chemistry and Pharmacology, Yale University

February 15, 2016: Advancing Your Research with CTSI Expertise – A special all-AHC faculty conversation
4-6 p.m., Mississippi Room, Coffman Memorial Union
Learn how the Clinical and Translational Science Institute (CTSI) is advancing and how CTSI's funding programs and expert resources can help bring your discoveries into practice. This informal event is for University researchers and will provide information on how best to use CTSI to advance your research projects and careers.

The event will include networking time, an informational program with a question and answer segment, and will conclude with expanded networking time to follow-up with presenters and connect with research colleagues.

The presentation portion of the event will be live streamed for faculty members outside the Twin Cities Metro area, and a recording will be available for those who cannot attend.

Hors d'oeuvres and refreshments will be served.  More information and registration details will soon be added to CTSI’s website. 

February 26, 2016: Forum on Ethical Issues in African Health Care
12-2 p.m., 2-101 NHH
This forum features three professionals conducting work and research in different regions of Africa and on very different aspects of health and health care. Each of them will talk about their work, with an emphasis on how ethics informs it and how their work derives new questions about what ethics means, for whom, and why. After discussion among the three, we encourage audience participation in continuing to debate the meaning of ethics, and how the many issues relating to health care across Africa push us to consider ethics in new ways. Visit the Center for Bioethics website for more information.

April 4, 2016: Save the date!: The 12th Annual Women’s Health Research Conference: Environmental Exposures and Hormones: Implications for Health
1-5 p.m., Coffman Theater, Coffman Memorial Union
Registration is now open.
Read more and submit an abstract.

April 25, 2016: Save the date! Minnesota HPV Vaccination Summit
The Masonic Cancer Center's Gynecologic Oncology Translational Working Group (Gyn Onc TWG) brings together cancer experts and healthcare leaders with one goal in mind: maximizing the success of research for the prevention and treatment of gynecologic cancers. Mark your calendar for Monday, April 25, 2016, for the Gyn Onc TWG's Minnesota HPV Vaccination Summit at the University of Minnesota.

Based on the same format as the national HPV vaccination summit held by the National Cancer Institute and Center for Disease Control last month at the MD Anderson Cancer Center in Houston, this day-long meeting will feature state and national HPV vaccination and cancer-prevention experts. We invite all of our interprofessional team of faculty and students, as well as partners from across Minnesota to actively participate in this historic cancer prevention summit. More information to follow.

May 9-10, 2016: 3rd Minnesota Neuro-Oncology Symposium
The mission of this Symposium is to educate researchers, clinicians, students, trainees, patients, caregivers, and community members on current and developing therapies for brain and nervous system tumors.

The Symposium with include two comprehensive programs designed to accommodate the specific interests of all those dedicated to finding a cure for brain tumors. The Research/Provider Program will present highly scientific content intended for researchers, physicians, students, and trainees. The Patient/Caregiver Program will present more practical information to patients, families, caregivers, and other community members with an interest in neuro-oncology. Visit the website.

May 9-10, 2016: REGISTER NOW!: Symposium on Germline Genetic Risk of Childhood Cancer: Where Do We Go From Here?
Organizers: Logan Spector, Ph.D., and Jenny Poynter, Ph.D.
Registration is free but attendance is limited to 100 persons.
Contact person:  Ginny Oie; email:

REGISTRATION IS FREE. Register online at

More information will be available on the Department of Pediatric's Epidemiology and Clinical Research website.

May 18-20, 2016: Save the date!: Midwest Tumor Microenvironment Meeting
The Masonic Cancer Center is hosting the  Midwest Tumor Microenvironment Meeting May 18-20, 2016. The conference goal is to leverage the strength of tumor microenvironment researchers in the Midwest to re-engineer the tumor microenvironment to improve tumor therapy/normalize the tumor microenvironment. The agenda and registration/hotel information is coming soon! Read more.

June 30, 2016: Save the date!: John H. Kersey Lecture
Alan Ashworth, Ph.D., FRS
E. Dixon Heise Distinguished Professor in Oncology, University of California San Francisco
President, UCSF Helen Diller Family Comprehensive Cancer Center
Senior Vice President for Cancer Services, UCSF Health
Professor of Medicine, Division of Hematology/Oncology, Department of Medicine

November 2-3, 2016: Save the date!: 7th Annual Masonic Cancer Center Research Symposium
TCF Bank Stadium
The 7th Annual Masonic Cancer Center Research Symposium is being held in honor of Lee Wattenberg, M.D.

Keynote Speaker:
The 2016 B.J. Kennedy Lecturer in Medical Oncology
Thomas Kensler, Ph.D., Professor, Environmental Health Sciences, Bloomberg School of Public Health; Professor Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine; Professor of Pharmacology and Chemical Biology, University of Pittsburgh

Registration and schedule information will be available later in the year.

Visit the Education and Training Opportunities web page for more conference and special lecture listings.

Back to top


February 20, 2016: Cancer and the Human Body
Science Museum of Minnesota, 120 W. Kellogg Blvd., St. Paul, MN

March 7-April 4, 2016: Mini-Medical School – Breakthroughs in Cancer Research and Treatment
Mondays, 6-8:30 p.m., for 5 weeks, Malcolm Moos Health Sciences Tower, Room 2-650, 515 Delaware St. SE, Minneapolis, MN 

Visit the website.

April 23, 2016: SAVE THE DATE for the 11th Annual Cancer Survivorship Conference
Saturday, April 23, 2016, 8 a.m. - 1:30 p.m.
McNamara Alumni Center, University of Minnesota
A cancer diagnosis can alter the landscape of your life. Although it doesn't redefine you, it can change your lifetime health care needs. Save the date for this free educational conference that focuses on questions and issues survivors and their families often face after cancer treatment or following stem-cell transplantation.

Registration is required and will open in early 2016. To be added to the conference mailing list, please click here.  

May 5-7, 2016: SAVE THE DATE! Promoting Health Equity Conference
Commons Hotel, Minneapolis
Details on the website.

May 9-10, 2016: 3rd Neuro-Oncology Program
The Patient/Caregiver Program will present more practical information to patients, families, caregivers, and other community members with an interest in neuro-oncology.

See more at

July 30, 2016: 2016 Marrow on the Move
Lake Nokomis, Minneapolis
Sponsored by the University of Minnesota Blood and Marrow Transplant Program
Contact:, 612-625-8942.

Visit the Events and Community Outreach page for more information.

Back to top

Funding Announcements and Opportunities

News & Notices:

Reminder - The V Foundation has announced its 2016 Translational Research and Scholar Awards!

The Translational Research Grant Program supports research teams to conduct translational cancer research to bring laboratory discoveries to the patient bedside. Each grant is $600,000 total awarded in three annual installments of $200,000.

The V Scholar Award supports young tenure-track faculty to begin their cancer research career in projects that are either laboratory-based fundamental research or translational research. Each grant will total $200,000 in two yearly installments of $100,000 each.

The MCC is allowed to nominate up to two proposals each for the Translational Research and Scholar Awards.

A one page description of the concept, a biosketch, and a draft budget in NIH format should be emailed to by 5pm Feb. 15th for consideration. The concept and budget will be reviewed by the MCC director and appointed committee to determine designation of nominee.

Masonic Cancer Center Review and designation of final applicant: February 22nd, 2016.

Foundation Deadlines: Application 5:00 EST, March 29th, 2016.

Please review eligibility and guidelines before applying and contact Elizabeth Fedie ( with any questions:

Funding Opportunities:
Postdoctoral Fellowship
American Cancer Society
This award is to support the training of researchers who have received a doctoral degree to provide initial funding leading to an independent career in cancer research (including basic, preclinical, clinical, cancer control, psychosocial, behavioral, epidemiology, health services and health policy research). Awards may be for three years with progressive stipends of $48,000, $50,000, and $52,000 per year, plus a $4,000 per year fellowship allowance (an additional $1,500 is added to the fellowship allowance in the last year to attend the ACS Postdoctoral Fellows Symposium or a domestic scientific meeting). Depending on availability of special endowment funds, the Society annually selects one or more of the top-ranked fellowships to be supplemented above the standard stipend.
Key Dates:
Application due April 1, 2016

DoD Lung Cancer Career Development Award
United States Department of Defense (DOD)
The goal of the FY15 LCRP is to eradicate deaths from lung cancer to better the health and welfare of military Service members, Veterans, their families, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer. The Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery.
Funding: The anticipated direct costs budgeted for the entire period of performance will not exceed $240,000.
Key Dates:
Pre-application due June 2, 2016
Full application due September 16, 2016

DoD Lung Cancer Idea Development Award
The Idea Development Award promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths from lung cancer. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.
Funding: The maximum period of performance is 2 years. The maximum allowable direct costs for the entire period of performance are $350,000 plus indirect costs.
Key Dates:
Pre-application due June 2, 2016
Full application due September 16, 2016

NCI Outstanding Investigator Award (R35)
The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for 7-year grants.
Funding:  Awards will be for $600,000 Direct Costs each year for seven years, plus applicable Facilities and Administrative (F&A) costs.
Key Dates:
Full application due November 23, 2016

Detection of Pathogen-Induced Cancer (DPIC) (R01)
This FOA is to encourage research projects which focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer (DPIC). It encourages research to assess molecular signatures associated with risk and early detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer.
Funding: Application budgets are not limited, but need to reflect actual needs of the proposed project.
Key dates:
Full application due July 10, 2016.

Research Answers to NCI’s Provocative Questions
RFA-CA-15-008 (R01)
RFA-CA-15-009 (R21)
The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.
Funding: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Key dates:
Full application due June 29, 2016

2016 LUNGevity Career Development Award in Lung Cancer Translational Research
LUNGevity Career Development Awards support future research leaders who will keep the field of lung cancer research vibrant with new ideas. The award, for translational early detection or therapeutics projects, including immuno-oncology projects, is open to junior faculty members who are within the first five years of their first faculty appointment.
Key dates:
Letters of intent are due by Wednesday, February 17, 2016.
Full application invitations: March 23rd
Full application Due: May 4th
Funding: $300,000 total over three years

2016 Pilot Grants in Health Disparities Research
Program in Health Disparities Research, University of Minnesota
Pre-application Webinar: February1 2, 2016, 8-10 a.m.
February 26, 2016: Letter of Intent from community-based organizations due
March 4, 2016: Community-academic teams invited to submit full application
May 2, 2016: Research proposals due
June 20, 2016: Grant awardees announced

The University of Minnesota Program in Health Disparities Research announces the 2016 Pilot Grants in Health Disparities Research. These grants are designed to encourage community-initiated research and foster sustainable long-term collaboration between community-based
organizations and academic researchers on research projects focused on reducing and eliminating health disparities.

Visit the Funding Opportunities Web page to see listings previously published in Update. A list of organizations that provide funding for cancer research is also provided there.

Back to top

Employment Opportunities

Researcher 2: Comparative Oncology
A Researcher 2 position is open in the laboratory of Dr. Jaime Modiano working on comparative oncology. A Bachelor (BS or BA) and/or a Masters (MS or MA) degree in life sciences (Biology, Immunology, Genetics, Biochemistry, or equivalent) or Basic Sciences (Chemistry or equivalent) and prior laboratory experience (>1 year) are required, including mastery of tissue culture and sterile techniques and especially handling hematopoietic cells and cancer cells. Highly desirable skills include proficiency in contemporary cellular, molecular, and biochemical techniques, including, but not limited to fundamental knowledge of methods in flow cytometry, isolation of proteins and nucleic acids, cell culture, PCR, RT-PCR, immunoblotting, cloning, transfection/transduction, sequencing, immunoprecipitation, immunofluorescence, microscopy, and digital imaging. Documented training in handling and working with laboratory mice is also desirable, particularly first aid and techniques such as tumor injection, adoptive transfer of cells, anesthesia, live imaging, and necropsy.

Prior experience (>6 months) in a laboratory with a fundamental understanding of purchasing systems and experience communicating with vendors and other company representatives, supervising graduate and/or undergraduate students, scheduling and coordination of laboratory meetings, and overseeing laboratory safety. Demonstrated capability in directing the technical aspects of a research project is preferred.

Qualified applicants should apply at the University of Minnesota Online Employment website at and use 307060 in the keyword search function.

Postdoctoral Positions in Cancer Bioengineering and Cancer Biology
Motivated postdoctoral associates are sought to join the Engineering in Oncology Laboratory of Dr. Paolo Provenzano at the University of Minnesota in Minneapolis, MN. Our laboratory studies the physical and molecular mechanisms driving cancer progression to metastasis and resistance to therapeutic intervention, and develops therapeutic strategies to re-engineer the tumor microenvironment.

A Ph.D. in the field of Biomedical Engineering, Biophysics, Cell Biology, Immunology, or a related field and a demonstrated (with 1st author publications) track record of productive research experience is required. See our ad in Nature for more information on the require qualifications. To apply please write to with the subject line:
Cancer Bioengineering/Biology Postdoctoral Position. Please include an up to date CV, 1-2 relevant publications in PDF format, and a brief description of your research interests and relevant background as related to our research program and your near term and long term goals. Letters of reference may be requested at a later date.

Postdoctoral Associate
A postdoctoral associate position is available in the lab of Ran Blekhman ( The lab uses genomics and computational approaches to study the mechanism of host-microbiome interactions and their role in colorectal cancer. The ideal candidate would be highly motivated to conduct independent research, and hold a PhD in genetics, bioinformatics, computer science, statistics, microbiology, or a related field, with a solid publication record. Candidates should have a strong analytical background, have experience with analysis of next-generation sequence data, and proficiency with computer and statistical programing languages. The successful candidates will enjoy a competitive salary and benefits package. Interested candidates are encouraged to contact Ran Blekhman by email (, and provide a brief cover letter detailing research experience and interests, a CV, and contact information for three references. Informal enquires are welcome. Applications will be accepted starting immediately and until the positions are filled.

Postdoctoral Associate
Dr. Bruce Walcheck, Immunology Program, is seeking a highly motivated individual for an NIH-funded postdoctoral position in leukocyte biology in inflammation and cancer. The Walcheck lab’s research is focused on the cell and molecular biology of leukocytes in the context of inflammation and the host response to cancer. Ectodomain shedding by specific membrane-associated proteases occurs in the microenvironment of the cell membrane of leukocytes and regulates the surface density of numerous receptors and the release of cell stimulatory factors. This process is central to the regulation of diverse leukocyte effector
functions, including their infiltration of tissue sites and killing of target cells. A better understanding of this proteolytic process may provide novel therapies for cancer and diseases resulting from excessive inflammation.

Interested applicants should email their CV and a cover letter with a statement of research interests to:

Postdoctoral Associate
Dr. Yoji Shimizu, Immunology Program leader, is recruiting a postdoctoral associate to investigate the mechanisms of action of novel mouse models of focal and scaffold-based
tumor immunotherapies. Applications from investigators with a recent or expected Ph.D. in biomedical sciences are encouraged. The ideal candidate will have demonstrated experience with laboratory mice and mouse cancer models, proficiency with flow cytometry, excellent oral and written communication skills, and an interest in developing independent research aims. Contact Dr. Yoji Shimizu ( or Dr. Brandon Burbach (

Postdoctoral Scholar
Two postdoctoral positions are available in the lab of Ben Hackel for a funded project on protein engineering of novel targeting ligands using an innovative combinatorial library approach. The lab, in the Department of Chemical Engineering and Materials Science, applies protein engineering technologies to develop in vivo molecular targeting agents for molecular imaging and targeted therapy, with a focus on oncology. We balance (1) fundamental study of molecular evolution and protein biophysics, which empowers our protein engineering efforts; (2) fundamental study of physiological transport of protein ligands, which guides improved delivery of molecular imaging agents and therapies; and (3) application of advances in these aims towards clinical challenges in disease detection and treatment. The current openings fall at the interface of (1) and (3). We seek motivated researchers with a Ph.D. in any related discipline as we value the diverse perspectives and expertise of an interdisciplinary environment. Experience in molecular biology and protein chemistry are beneficial. A demonstrated record of scientific achievement, including publications and presentations, is essential. A successful candidate will demonstrate strong work ethic, creativity, and productivity. Please send a brief description of your career goals, your curriculum vitae, and contact information for three references to  

Web Developer, Oncology Medical Informatics Services
A Web Developer position is available to work with project and business teams to understand business requirements and analysis plans associated with data initiatives, to design the right solution and consult on best practices and code reviews, and to participate as a team member and assist other team members as needed.   Oncology Medical Informatics & Services (OMIS) provides technology and data mining support to its customers who include principal investigators and their teams, the Clinical Trials Office, Translational Cell Therapy Lab and individual cancer center members. We manage patient registries such as the outcomes registry for the BMT Program. The OMIS team also supports the center's administrative office by providing metrics and clinical trial accrual data to comply with the National Cancer Institute's Cancer Center Support Grant guidelines.  Interested individuals should go to the Employment System to search and apply for the following job opening: 307114 (Web Developer).

Regulatory Assistant
The Masonic Cancer Center Clinical Trials Office is currently recruiting a Regulatory Assistant to support regulatory management of interventional clinical trials in oncology and provide administrative support for the therapeutic and non-therapeutic Cancer Protocol review Committee (CPRC). This position requires proficiency with Microsoft Office and electronic calendaring, experience collaborating with external customers and with forms, tables and databases.  Interested individuals should go to the Employment System to search and apply for the following job opening: 307487 (Regulatory Assistant).

Clinical Data Associate II, Clinical Trials Office
The Masonic Cancer Center Clinical Trials Office (CTO) is currently recruiting a Clinical Data Associate. The primary purpose of the Clinical Data Associate (CDA II) position is to conduct research subject registration and yearly follow-up for the University of Minnesota’s Blood and Marrow Transplant Database and for the Center for International Blood and Marrow Transplant Research (CIBMTR) as part of reporting requirements.  A bachelor’s degree in a health-related field and 2 years of experience in a medical or scientific field or a combination of related education and work experience to equal 6 years is required.  Qualified candidates will have experience with blood or marrow transplants including terminology, obtaining Authorization of Release of medical information, medical data abstraction, EMR systems and experience working in a research setting.  Interested individuals should go to the Employment System to search and apply for the following job opening: 306820 (Clinical Data Associate II). 

Operations Manager, Clinical Trials Office
The Masonic Cancer Center Clinical Trials Office (CTO) is currently recruiting an Operations Manager to partner with the CTO Director to increase the efficient use of resources, streamline the start-up phase of all oncology clinical trials, maintain and manage the budget and ensure ongoing and up-to-date staff training. This position will also manage and lead Project Management personnel which will require facilitating successful interactions with key functional groups which include Clinical Teams, Data Management, MHealth, FRA, UMP, CTSI, Financial Hub, PIs, Quality Assurance.  The qualified candidate will have a bachelor’s degree and 8 years’ experience in medical research to include project management of clinical trials, supervisory experience and clinical research certification.  Interested individuals should go to the Employment System to search and apply for the following job opening: 306822 (CTO Operations Manager). 

Clinical Research Nurse Coordinators – Solid Tumor
The Masonic Cancer Center Clinical Trials Office is currently recruiting Clinical Research Nurse Coordinators for solid tumor interventional trials. Clinical trials include Phase I-II trials under locally held INDs, as well as Phase II/III industry sponsored trials. The Clinical Research Nurse coordinates all aspects of a portfolio of clinical trials including patient management and safety, protocol administration, and educating and training research staff, clinical staff, medical providers, patients and their families. Conducts, coordinates and serves as a resource for various aspects of clinical trials from start-up to closeout according to study protocols. Interested individuals should go to the Employment System to search and apply for the following job openings: 305776 (Research Nurse) and 305715 (Senior Clinical Research Nurse).

Principal Office and Administrative Specialist
Working in the Masonic Cancer Center’s administrative office, the Principal Office and Administrative Specialist provides general office support including reception, conference room management, expense reimbursements and reconciliation, etc.; and specific support for operations and human resources.   This position requires advanced proficiency in Microsoft Office and electronic calendaring and with forms, tables and databases. Interested individuals should go to the Employment System to search and apply for the following job opening: 306546 (Prin Ofc & Admin Specialist).

Functional Genomics of GI Tract Cancers Discover Team Recruitment
The University of Minnesota Medical School, in collaboration with the Masonic Cancer Center, is focusing efforts to hire outstanding physicians, researchers, and bioinformaticists for a Discovery Team to work on functional genomics of gastrointestinal (GI) tract cancers. This new team will build off current research, leverage the teams and shared resources already in place, as well as bring their own research interests to develop new technologies and models for understanding tumor heterogeneity.

We are seeking a dynamic mid-career or senior physician scientist with training in pathology or medical oncology to lead this effort and are conducting a national search to find the right person. The successful candidate will be expected to assume the leadership role for existing faculty and future hires, and expand a comprehensive program in GI cancer spanning basic science, translational genomics, and clinical trials. The successful candidate will be appointed with tenure in the Department of Medicine’s Division of Hematology, Oncology and Transplantation or the Department of Laboratory Pathology. Visit the job posting (#301436) for more information.

Back to top

  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on February 9, 2016